Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Skip to main content

Healthcare & Pharmaceuticals

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

2 minute read

A sign is pictured outside an Eli Lilly and Company pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar

April 16 (Reuters) - Eli Lilly and Co (LLY.N) said it had requested for cancellation of the U.S. authorization granted to its COVID-19 antibody, bamlanivimab, which will now be used in combination with another to achieve greater efficacy against emerging virus variants.

The request made to the U.S. Food and Drug Administration is not due to any new safety issues, but in response to the new variants in the country that could be resistant to bamlanivimab when used alone, the drugmaker said in a statement.

The U.S. government stopped the distribution of the therapy last month.

Hospitals with bamlanivimab supply should now order etesevimab to pair with it, Lilly said.

Earlier this week, Lilly revised its pact with the U.S. government to enable the supply of etesevimab to complement doses of bamlanivimab that the government had already purchased. read more

Etesevimab and bamlanivimab together neutralize more emerging COVID-19 variants in the U.S. than bamlanivimab alone, including the rapidly growing B.1.427/B.1.429 California strain, Lilly said on Friday.

Lilly said it was not seeking cancellation of bamlanivimab's authorization in other countries, but its use was preferred in combination with etesevimab.

The drugmaker said it expects to make enough of the cocktail therapy along with partner Amgen (AMGN.O) to meet global supply needs.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Amy Caren Daniel

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters